In 1817, James Parkinson published “An Essay on the Shaking Palsy,” the first such recognition of a disease that eventually would be known by his name. On April 11, World Parkinson’s Day and the 267th anniversary of Parkinson’s birth, and throughout the month, the Parkinson’s community will raise awareness about…
Vyant Bio and OrganoTherapeutics are teaming up to speed the discovery of new candidates for treating Parkinson’s disease. The collaboration will leverage OrganoTherapeutic’s patient-derived “mini-brains” — midbrain organoids — derived from induced pluripotent stem cells (iPSCs) and Vyant Bio’s expertise in machine learning technology to identify new…
ABBV-951, a continuous infusion formulation of levodopa/carbidopa, brought comparable levels of levodopa into the bloodstream of healthy volunteers as surgically implanted levodopa-carbidopa intestinal gel (LCIG), a Phase 1 study confirmed. Because the delivery of doses can be tailored to a patient’s needs, this alternative form of delivery — a portable…
The first patient has been dosed in a Phase 3 trial testing GE Healthcare’s new dopamine transporter positron emission tomography (PET) tracer, which is designed to aid in the evaluation of adults with suspected parkinsonian syndromes, including Parkinson’s disease. The PET agent is a…
IMAC Holdings has started dosing the third and final group of participants in a Phase 1 clinical trial assessing the potential of its umbilical cord-derived stem cell therapy for treating bradykinesia, an early motor symptom of Parkinson’s disease characterized by slowness or difficulty in movement. The open-label trial…
Injecting acidic nanoparticles into mice in a model of Parkinson’s disease protected against nerve cell loss and restored the ability of lysosomes, cell compartments responsible for breaking down excess or damaged proteins, to work as they should, a research team reported. “Our results support lysosomal re-acidification as a disease-modifying strategy for…
Treatment with the low-dose painkiller ketamine eased levodopa-induced dyskinesia (uncontrollable body movements) in patients with Parkinson’s disease, according to results from a Phase 2 study sponsored by PharmaTher. The trial (NCT04912115) evaluated how well a low dose of ketamine that does not induce anesthesia works to reduce levodopa-induced…
Based on survey results indicating that pandemic restrictions considerably aggravated Parkinson’s disease (PD) symptoms and hampered care, Parkinson’s UK is calling on its various governments to take remedial steps to improve both care and access. Calls for action derive from a 41-page report by the nonprofit organization and Lancaster…
Treatment with oral IPX-203, Amneal Pharmaceuticals’ investigational extended-release carbidopa-levodopa (CD/LD) formulation, reduced “off” time by about 1.5 hours a dose, on average, compared to immediate-release tablets of the medication, according to data from a Phase 3 RISE-PD clinical trial. Top-line results from RISE-PD were announced last year. Detailed…
To celebrate Parkinson’s Awareness Month, this year’s INSIGHT into Parkinson’s meeting will be the longest World Parkinson’s Day conference to date and focus on research updates and practical suggestions to improve the lives of people with Parkinson’s disease. World Parkinson’s Day takes place on April 11, and April…
Get regular updates to your inbox.
